Clinical Trials

Provision Center for Biomedical Research serves as an independent research site, consistently delivering excellence in patient care and study performance that meets research requirements and builds strong relationships with physician and sponsor partners.

Listed below are Active and Upcoming Clinical Trials. “Active” status means that Provision Center for Biomedical Research is actively involved in the trial, which may or may not be accepting new patients. Active status has two types: “Active: Open to Patient Enrollment” status is in the patient recruitment phase, where patients are welcome to enroll, provided they meet the study criteria; or “Active: Closed to Patient Enrollment”, where the study is still active in collecting data, but is closed to enrolling new patients. Should patients be interested in a trial that is closed to enrollment, they may inquire about other studies where they might qualify to participate.

If you would like more information on our clinical trials or want to learn more about enrollment, please CONTACT US

Active and Upcoming Clinical Trials

Listing Title
Listing Category
Description

A phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Monica Crane, Genesis Neuroscience Clinic
Listing Title
Description

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Title
Description

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Title
Listing Category
Description

A Phase 2, Double-blind, Randomized, Placebo controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Category
Description


A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Monica Crane, Genesis Neuroscience Clinic
Listing Title
Listing Category
Description


Alzheimer’s Network for Treatment and Diagnostics. Observational study for patients who are being treated with Novel FDA approved therapies.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Monica Crane, Genesis Neuroscience Clinic
Listing Title
Description


A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Title
Description


A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-Label Extension

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Title
Description


A Phase 2b/3, Randomized, Double-Blind, Placebo- Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Description


Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) (IMPAHCT-FUL)

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Scroll to Top